TABLE 3.

Parameter estimates for logistic regression model for probability of being cured versus CSF, C_ss,_min, and model estimated plasma AUC in a 6-h dosing interval^a

Parameter by enantiomerb	Median (5th and 95th percentiles):
	Slope	Intercept
CSF
l-Eflornithine	0.116 (−0.0278, 0.417)	−0.499 (−3.86, 31.5)
Total eflornithine	0.0460 (−0.00448, 0.155)	−0.841 (−4.70, 1.66)
Css,min
l-Eflornithine	0.0343 (0.0103, 0.0891)	−1.82 (−5.83, 0.741)
Total eflornithine	0.0125 (0.00393, 0.0327)	−2.17 (−6.80, 0.423)
AUCτ
l-Eflornithine	0.00865 (0.00345, 0.0272)	−4.47 (−15.2, −0.843)
Total eflornithine	0.00368 (0.00178, 0.0914)	−6.07 (−16.8, −2.32)

^aCSF, cerebrospinal fluid; C_ss,min, average trough concentration at steady state. The estimates are presented as the median and 5th and 95th percentiles based on 1,000 data sets generated by a nonparametric bootstrap of the original data set.

^bCSF concentrations are the average concentrations on days 10 and 15 (n = 2). C_ss,min is the average plasma concentration prior to the next dose or 6 h after the last dose (n = 3). AUC_τ is the area under the plasma concentration-time curve in the dosing interval (τ = 6 h). The total eflornithine is the sum of the l- and d-eflornithine concentrations. The bootstrap estimates correspond to parameters by bootstrapping 1,000 data sets for each enantiomer and exposure measurement. Runs without successful conclusion (“MINIMIZATION SUCCESSFUL”) were omitted for analysis (n = 1 to 29); 979 to 999 runs were included when calculating the percentiles.